Pharma Marketing News – Reprints

---

Reprints of Past Articles

Choose a Reprint Topic Area Physician Marketing, Sales, and Education

• Physician Education (CME)
• Physician Marketing & Promotion
• MSLs and KOL Management
• Sales Force Effectiveness

Consumer Marketing and Education

• Direct-to-Consumer (DTC) Advertising & Marketing
• Compliance Marketing & Education
• Patient Education

Marketing Techniques and Tools

• Market Research
• Customer Relationship Management (CRM)
• Brand Marketing
• Relationship Marketing
• eMarketing and ePromotion

Regulatory Compliance, Privacy and Strategy

• Regulatory Compliance
• Strategic Marketing & Planning

Miscellaneous

• Product & Service Reviews — Where the rubber meets the road!
• Global Pharma Marketing Practices — Thinking outside the States!

Choose a Reprint by Date of Publication Choose year:
2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 |

2011

August 23, 2011 (Vol. 10, Issue #13)
Executive Summary of Complete Issue

• British Pharma Digital Update: Insider Reactions to Social Media Guidelines from Industry Regulators
• Four Useful Lessons Pharma Can Learn from the Pfizer Facebook Hack
• PR & Interactive Agencies Vie for Pharma Social Media Campaign Crumbs
• Pharma Facebook Pages Being Phased Out: A Good Run While It Lasted!
• Vast Majority of Drug Ads in Leading Medical Journals Don’t Pass MDs’ Sniff Test!

July 20, 2011 (Vol. 10, Issue #12)
Executive Summary of Complete Issue

• Adobe Connect for eDetailing
• The Digital Health Coalition – Podcast
• Citizen Petition Likely to Delay FDA Social Media Guidance
• Tracking Public Health Trends: Twitter vs Google vs Your Nose
• Pfizer, Show Us Your Social Media “Playbook”
• FDA is Monitoring This Blog and Perhaps You Too!

June 21, 2011 (Vol. 10, Issue #11)
Executive Summary of Complete Issue

• Finding the Consumer Within the Patient
• Adobe Connect for eDetailing – Podcast
• Fair Social Media Practice Principles
• Majority of Review-Worthy Bad Ad Complaints were Submitted by Pharma
• The Twelve Steps of Pharma Social Marketers Anonymous

June 8, 2011 (Vol. 10, Issue #10)
Executive Summary of Complete Issue

• The Pharmaguy Social Media Timeline™
• Finding the Consumer Within the Patient – Podcast
• New Facebook Policy “Kind of Hurts” Pharma Marketers
• FDA, DOJ, & Google: Conspiracy Theory, Part 2
• FDA Drops “Social Media” from Its 2011 Guidance Agenda
• First FDA Social Media Guidance to Address Responding to “Unsolicited Requests” for Off-label Information

May 18, 2011 (Vol. 10, Issue #9)
Executive Summary of Complete Issue

• Pharma SmartPhone/Tablet Apps: Is There a Regulation for That?
• Challenges of Regulating Mobile Medical Apps
• FDA’s BadAd Program Lacks Credible Evidence
• eDetailing Technology & Birth of “Sales Cyborg”
• Physicians Are Concerned That Pharma Supported CME is Biased, But …
• FDA v. Google & Those 14 Infamous Warning Letters

April 28, 2011 (Vol. 10, Issue #8)
Executive Summary of Complete Issue

• Physicians Favor Brands With a Compelling Adherence Program
• Implications of Facebook’s Page Commenting Changes
• A New Estimate of Drug Development Cost
• FDA Plans to Test New Standard for Easy to Understand Rx Labels
• FDA’s Bad Ad Program is “Phoniest Thing Ever!”
• Pharma Even More Digitally Feeble When it Comes to Healthcare Providers

April 15, 2011 (Vol. 10, Issue #7)
Executive Summary of Complete Issue

• The Changing Role of Pharma Sales Reps
• Mining Mobile Health App User Data
• (Little) Used Drug for Sale. GSK Says, Bye Bye Alli!
• Ad Dollars Follow Eyeballs to Web
• Phil Mickelson is Now Regulated by FDA
• Brits Beat FDA & PhRMA: Issue Social Media Guidance for Pharma

March 30, 2011 (Vol. 10, Issue #6)
Executive Summary of Complete Issue

• Adverse Event Reporting: A Missed Opportunity
• Pharma TeleWeb e-Detailing
• Physicians Favor Brands with Compelling Adherence Platform
• Are Sales Reps as “Useful” as PhRMA Wants Us to Believe?
• Astellas Scientist Shows How to Light Ice on Fire!
• FDA Promises Still More Guidance! This Time It’s Mobile.

March 10, 2011 (Vol. 10, Issue #5)
Executive Summary of Complete Issue

• Pharma Twitter Pioneers Recognized
• Evidence-Based Pharma Marketing
• Astrazeneca’s Twitter Survey: Will They Share Some Results?
• Method Acting for Real Patients Who Play Themselves on Pharma YouTube Channels

February 23, 2011 (Vol. 10, Issue #4)
Executive Summary of Complete Issue

• Will Critics Kill Pharma’s Social Media Golden Egg Laying Goose? (pdf)
• HCP Marketing Beyond the Physician: Plugging Into NPs and PAs
• Google’s New OneBox Rx “Ads” Steal Clicks from Organic Branded Rx Search Results
• OMG! AstraZeneca Hosts Twitter Chat & World Does NOT End!
• AstraZeneca Hosts “Take on Depression” Facebook Discussion – Seroquel Lurks Behind the Scenes
• Phil Mickelson “Opens Up” to Arthritis Today Magazine

February 17, 2011 (Vol. 10, Issue #3)
Executive Summary of Complete Issue

• Good Promotion Practices Alliance
• Breaking the 140-character Limit of Twitter Opens the Door to FDA-Compliant Branded Tweets
• FDA’s Abrams Spends 4 Minutes Discussing Social Media Guidance at ePharma Summit!
• The Socialisation of the Internet is Bogus
• GSK’s U.S. Sales Reps “Europeanized”: No Longer Rewarded for Ability to Push Prescriptions

January 19, 2011 (Vol. 10, Issue #2)
Executive Summary of Complete Issue

• Deal with Lack of Regulations by Developing Best Practices (pdf)
• Strategies for Marketing Compliance
• Getting Market Research Right in India & China

January 12, 2011 (Vol. 10, Issue #1)
Executive Summary of Complete Issue

• Welcome to the 2010 Pharma Marketing YearBook™
• Events I Witnessed, News You Made, & People We Met
• Pharma Social Media Trials & Tribulations
• Pharma Spending on Internet, DTC, and Docs
• Pharma Companies Behaving Badly

---

2010

December 2010 (Vol. 9, Issue #10)
Executive Summary of Complete Issue

• Up Front: Pharma’s 2010 Christmas Wish List for Santa
• New Media Privacy Issues & Online Health Marketing
• Pfizer’s Latest Lyrica DTC Ad Should Be Cited By FDA as Misleading
• Ad Execs Not Viewed as Innovative By Americans Says AstraZeneca Survey
• Pfizer’s Sales Reps Have 48 Hours to Out Deliver eSampling Program

November 2010 (Vol. 9, Issue #9)
Executive Summary of Complete Issue

• Up Front: Pharma Collaboration with Online Patient Opinion Leaders
• Physician-Generated Content on Social Media Sites
• Getting Market Research Right in the Middle East
• Capturing & Reporting HCP-Related Meeting Spending

October 2010 (Vol. 9, Issue #8)
Executive Summary of Complete Issue

• Up Front: Social Media and the Limitations of Disease Awareness Campaigns
• Integration of Custom Media into the Marketing Mix
• Digital Pharma Is Alive and Well in Europe!
• Getting Market Research Right in Emerging Markets

September 2010 (Vol. 9, Issue #7)
Executive Summary of Complete Issue

• Up Front: Solving the Adherence Problem in Economic Hard Times
• Pharma, Physicians, and Sermo
• Eyes on the Adherence Prize
• Closed-Loop Patient Education

Summer 2010 (Vol. 9, Issue #6)
Executive Summary of Complete Issue

• Up Front: Just-in-Time Publishing
• The iPad as a Pharma Marketing Platform
• Social Media Leaders Wanted
• The Pharmaguy Next Door

May 2010 (Vol. 9, Issue #5)
Executive Summary of Complete Issue

• Up Front: Pharma Crisis Communications in the Fast-paced World of Twitter et al
• The Changing Pharma Commercial Model in 2010 and Beyond
• ePrints NRx for Physician Detailing
• Data Mining in the Deep, Dark Social Networks of Patients

April 2010 (Vol. 9, Issue #4)
Executive Summary of Complete Issue

• Up Front: What’s Your Social Media Implementation Plan?
• Real Patient Testimonials
• How to Manage the Online Conversation
• Moderation Best Practices for Pharma Social Networks
• Use of Social Media for Health Purposes in the EU

March 2010 (Vol. 9, Issue #3)
Executive Summary of Complete Issue

• Up Front: FDA Can Relax. I Did All the Work for Them!
• Industry and Consumer Advocates Square Off Regarding Social Media
• Overcoming Space Limitations in Social Media
• Accountability for Pharma Content on Social Media Sites
• Solving the Social Media Adverse Event Reporting Problem

February 2010 (Vol. 9, Issue #2)
Executive Summary of Complete Issue

• Up Front: Waiting for Goduidance
• Use of Twitter for Patient Support
• Building the “New” Pharma Physician Marketing Model
• Pharma’s Social Media Working Group
• Use of Behavioral Targeting by Pharma Marketers

January 2010 (Vol. 9, Issue #1)
Executive Summary of Complete Issue

• Up Front: Healthcare Communications vs. Pharma Marketing
• Predicting the Future of the Drug Industry
• Corporate Reputation in the New Media World
• Pharma Begins to Reveal Payments to Physicians

---

2009

November/December 2009 (Vol. 8, Issue #10)
Executive Summary of Complete Issue

• Up Front: What’s Next from the FDA?
• Consequences of Direct-to-Consumer Advertising
• Search Advertising Options for Pharma
• A Few Things I Learned at FDA’s Social Media Hearing
• Pharma’s Image Conundrum: Building Brand Loyalty and Consumer Confidence

October 2009 (Vol. 8, Issue #9)
Executive Summary of Complete Issue

• Up Front: Fear and Loathing in Washington, DC
• Social Media Adverse Event Reporting Safe Harbors: It’s Time for FDA to Open Up the Internet to Rx Advertising Like It Did with TV!
• Pharmaceutical Market Access 2010: Strategic Developments Impacting the US, EU, and Emerging Markets
• Risk Mitigation and Its Impact on Pharma Marketing: Appropriate Use Benefits After Launch

September 2009 (Vol. 8, Issue #8)
Executive Summary of Complete Issue

• Up Front: Let’s Respond to FDA’s Questions Regarding Its Regulation of Social Media
• What If There Were No Rules in Pharma Marketing?: Be Sure Not to Cut Off the Ends of Your Ham
• Pharma-Sponsored Medical Ghostwriting: What the Ghosts Have to Say About It
• Pharmaguy’s Twitter Followers: What Do They Want and How Is It Relevant to You?

August 2009 (Vol. 8, Issue #7)
Executive Summary of Complete Issue

• Up Front: Social Media & the Truncated News Pyramid
• Owning the Prescription Pad: Driving Brand Decisions in a Multi-Influence World
• Social Communications in Healthcare: Summary of Roundtable Discussions
• Waning Pharma Support of CME: The Plight of For-Profit MECCs

June/July 2009 (Vol. 8, Issue #6)
Executive Summary of Complete Issue

• Up Front: Whither Twitter for Pharma?
• Pharma Marketers Dive Deeper Into Social Media: The Good, the Bad, & the Ugly Case Studies
• How Should Pharma Engage in Social Networks?: Thoughts on Best Practices
• FDA Draft Guidance on Risk: Reading the Tea Leaves

May 2009 (Vol. 8, Issue #5)
Executive Summary of Complete Issue

• Up Front: Will the Drug Industry be the Next Auto Industry?
• Protection from Brand Infection: Marketers Must Take Control of Their Brands, Especially Online
• Ramifications of FDA Regulatory Actions: Helping FDA Find a New Media Regulatory Pathway
• The New PhRMA Code and Beyond: Federal & State Laws are Eclipsing Self-Regulation
• From Nalty to “Nalts”: The Transformation of a Pharma Marketing Director into a “Viral Video Genius”

April 2009 (Vol. 8, Issue #4)
Executive Summary of Complete Issue

• Up Front: Social Media–Opportunity or Nightmare?
• Developing Guidelines for Pharma’s Use of the Internet & Social Media: A Call for a Public Hearing at FDA
• The Empowered Patient: What It Means for Pharma Marketers
• Socially Challenged Pharma: How Ready is Pharma to Engage In Social Media?
• Report from the Social Pharmer “Unconference”: Sowing Seeds of Social Media Change?

March 2009 (Vol. 8, Issue #3)
Executive Summary of Complete Issue

• Up Front: Syndication is da Bomb!
• Pharma’s Bad Rep or Bad Rap: Whatever! The Drug Industry Must Earn Back the Public’s Trust
• Will Healthcare be Rationed or Rational?: A Case for Supporting Comparative Effectiveness Research
• FDA’s Use of Social Media: Peanuts Today, Drugs Tomorrow!
• New Privacy Rules in Economic Stimulus Law: Will They Restrict Certain Pharmaceutical Marketing Practices?

February 2009 (Vol. 8, Issue #2)
Executive Summary of Complete Issue

• Up Front: My Pledge to Subscribers & Advertisers
• The View From ePharma Summit: Practicing What Was Being Preached!
• Building the Optimal Service Model: Creating the Right Physician Experiences to Drive Business
• The New Rules of Marketing & PR: Book Review and Insights for Pharma
• Sales Force Effectiveness Metrics: More Important Than Ever in a Tough Market

January 2009 (Vol. 8, Issue #1)
Executive Summary of Complete Issue

• Up Front: Is There Life After Pharma?
• The Future of DTC Advertising: Is a Perfect Storm Brewing?
• The ePharma Pioneer Club™: Convincing Pharma Marketers to Engage in “e”
• FDA Finalizes Guidance on Distribution of Reprints
• The Hypocrisy of Healthcare Marketing Restrictions: Stand Up for Healthcare Marketing Free Speech

---

2008

December 2008 (Vol. 7, Issue #10)
Executive Summary of Complete Issue

• Up Front: Prepare or Die!
• The Changing Policy Landscape: Prepare Now for the Coming FDA and Pharmaceutical Marketing Reforms
• Patient Assistance Program Rankings: Going Beyond Sales Force Effectiveness to Customer Experience Satisfaction
• Critical: What Daschle Plans to Do About the Healthcare Crisis
• Reforming the FDA: It All Starts with a New Commissioner!

November 2008 (Vol. 7, Issue #9)
Executive Summary of Complete Issue

• Up Front: Time for a New & Improved FDA Commissioner
• Free Drug Samples: The Sales Rep’s Last Great Hope?
• Optimizing Market Access: A Guide to Effective Pricing, Reimbursement and Messaging Strategies
• Measuring & Communicating eSuccess: Strategy First, YouTube Later… Maybe

October 2008 (Vol. 7, Issue #8)
Executive Summary of Complete Issue

• Up Front: Good Luck to Us All!
• Obama v. McCain Survey Results
• Medical Device Marketing
• Global Pharma Competitive Intelligence
• The State of CME in Europe
• Turning Science into Sales

September 2008 (Vol. 7, Issue #7)
Executive Summary of Complete Issue

• Up Front: Who’s Better for Pharma: Obama or McCain?
• PhRMA’s New Code on Interactions with Healthcare Professionals
• Building Power Sales Messages
• Current Issues and Future Prospects for Sales Force Effectiveness
• India’s Booming Pharmaceutical Market

June/July 2008 (Vol. 7, Issue #6)
Executive Summary of Complete Issue

• Up Front: Going Global, Networking Reception Highlights, Vendor Video Showcase
• Why Pharmaceutical Marketers Ignore ROI
• Creating the Most Effective Sales Calls
• Diversity in the Life Sciences
• Value-based Pricing

May 2008 (Vol. 7, Issue #5)
Executive Summary of Complete Issue

• Moving the Needle on Adherence
• High Impact Content in Support of Rx Brands
• How to Get Your Message In Front of Pharma Brand Managers

April 2008 (Vol. 7, Issue #4)
Executive Summary of Complete Issue

• DTC Risk Communication
• Building a Blockbuster
• Guerilla Pharma Marketing
• Reporting Gifts to Physicians

March 2008 (Vol. 7, Issue #3)
Executive Summary of Complete Issue

• I’m All a Twitter Over Twitter
• The Coming Pharma Marketing Recession
• Tips for Improving Pharma Sales
• What Americans Think About Drug Advertising
• Closed Loop Marketing
• Pharma’s Social Media Marketing Readiness Score

February 2008 (Vol. 7, Issue #2)
Executive Summary of Complete Issue

• Jarvik: A Modern DTC Tragedy
• FDA’s Good Reprint Practices Guidance
• Helping Pharma eMarketing “Grow up”
• Understanding the Strategic Value of MSLs
• Prescription Drugs and the Health 2.0 Opportunity

January 2008 (Vol. 7, Issue #1)
Executive Summary of Complete Issue

• DTC User Fees Go PDUffft!
• Use of Celebrities for PR and DTC Advertising
• Pharma Marketing Network 2007 Report
• Wither CME?
• Is It Time to End Industry Sponsored CME?
• Cholesterol Drug Users Discuss Their Medication

---

2007

November/December 2007 (Vol. 6, Issue #10)

• Diversity in Pharma
• Mapping New Paths through the DTC Marketing Mix Maze
• Accomplishing Adherence
• Medical Transcript Advertising
• Pharma Marketing Roundtable – Members Only!
• New Social Media Regulatory Framework

October 2007 (Vol. 6, Issue #9)

• Awards. What Are They Good For?
• Collaborating with Online Physician Communities
• Rep Access Programs
• Re-Designing the Pharma Sales Force
• Pharmaceutical Competitive Intelligence

September 2007 (Vol. 6, Issue #8)

• DTC, for Better or Worse, is Here to Stay
• Surviving the Election Wars
• Web 2.0 Pharma Marketing Tricks for Dummies
• Measuring Consumer Sentiment About Prescription Drugs
• Pharma Marketing Stuck in Web 1.5

July/August 2007 (Vol. 6, Issue #7)

• J&J’s PR Hindenburg Disaster!
• Merck Rejiggers Its Marketing Mix
• Stop Wasting $Millions on Ineffective DTC Ads!
• The Changing Landscape of Physician Interactions
• A Tale of Two Pharma Whistleblower Novels

June 2007 (Vol. 6, Issue #6)

• One…uh, Two Small Steps for Pharmaco Blogging!
• SiCKO is Boffo but Not Anti-Pharmaco Per Se
• Big Pharma Sales Analytics for the Rest of Us
• Got Game? Online Pharma Advergaming
• From Science to CEO: The Scientific Path to Corporate Leadership

May 2007 (Vol. 6, Issue #5)

• Moore: Please Don’t Ignore Us Pharma Bloggers
• Measuring an Intangible: Medical Science Liaison Metrics Consensus
• Optimizing Brand Equity: Pre-Launch through Patent Expiry and Beyond!
• Mobile Pharma Marketing: What’s the 411?
• Murky Physician Marketing and Education Practices

April 2007 (Vol. 6, Issue #4)

• Full Disclosure
• How Readable, Credible & Useful are Pharma Blogs?
• Targeted Faith-based Disease Awareness Marketing
• Americans Skeptical of Pharma Cause Marketing
• YouPharma: New Rules for Pharma Marketing and Social Media
• A Primer on Pharma Employee Blogging

March 2007 (Vol. 6, Issue #3)

• Should Bloggers Dine at Pharma’s Table?
• Disease Mongering: When Is the Line Crossed?
• Innerstate: The First Disease Awareness Documentary Film
• Are Pharma Bloggers Biased Against the Industry?

February 2007 (Vol. 6, Issue #2)

• God Bless R&D, but Marketers May Go to Hell!
• The Expanding Pharma Blogosphere
• Surfing the eMarketing Big One!
• Social Network Marketing: The Wisdom of the Crowd
• What’s Next vs. What’s Best

January 2007 (Vol. 6, Issue #1)

• Word-of-Net
• Are Sales Reps Necessary?
• Reinventing the Sales Model
• Sales Reps Debate Their Value
• An Online Community to Call Our Own

---

2006

November/December 2006 (Vol. 5, Issue #10)

• Betting the Pharm
• Congress vs. Pharma: Trouble Ahead?
• Pharma’s Plodding Approach to eMarketing
• Sales Effectiveness Meets eMarketing
• Teaching New Dogs Old Tricks

October 2006 (Vol. 5, Issue #9)

• Interpretation of Ads
• e-Inertia Plagues the Pharma Industry
• Optimizing DTC Performance
• The Brand Marketing Mix
• Pharma Online Spending

September 2006 (Vol. 5, Issue #8)

• Numbers
• Print DTC: How Does It Measure Up?
• Fast Start to Customized ePromotion and eLearning Physician Programs
• Pharma’s Black Knight Confesses All!
• Pharmacy TeleStocking

July/August 2006 (Vol. 5, Issue #7)

• Engagement
• PR: Advertising by Other Means
• Relationship Marketing via eNutrition
• Physician Meetings: Education Works Both Ways
• MSL Roles & Goals

June 2006 (Vol. 5, Issue #6)

• Could Chill Kill CME?
• Trends in Commercial Support of CME
• Slides: The Currency of Communication
• Free Prescription Drug Cards
• Whose Data Is It Anyway?

May 2006 (Vol. 5, Issue #5)

• Doing a Good Job but Still Not Trusted!
• The Changing World of MSLs: Determining Value
• Biotech DTC: Business Not As Usual
• Peter Rost: Whistle Blower, Pharma Blogger, ???

April 2006 (Vol. 5, Issue #4)

• Disease Mongering
• Communicating Risk: Let the Dialog Begin
• Merit of CHC Petition to FDA
• Managing Reprints for Better Clinical Support of Marketing
• The Electronic Formulary Will Change the Equation

March 2006 (Vol. 5, Issue #3)

• Buzz ‘n Blog Marketing
• The European eMarketing Scene: Desperately Seeking Strategy
• European Online Marketing Survey Results
• Effective Physician Marketing at Medical Meeting Exhibits
• Paid Inclusion: Too Hot for Pharma Marketing?

February 2006 (Vol. 5, Issue #2)

• Pharma McCarthyism
• Free Gifts to Physicians: What’s the Big Deal?
• What Pharma Companies Spend on Gifts to Docs
• Branded Physician Education: How to Integrate Promotion and Education
• Hard Sell: The Evolution of a Generation X Salesman

January 2006 (Vol. 5, Issue #1)

• The End of DTC as We Have Known It
• Pharma Trends to Watch in 2006
• Direct to Physician Telemarketing and Sales
• Pfizer France: Viva la SFE Difference!
• Women in Pharma

---

2005

December 2005 (Vol. 4, Issue #11)

• “Tribal Marketing”
• Blogs and the Pharmaceutical Industry
• DocCheck: Das Portal
• Generation Rx: A History and Critique of Pharma “Tribal Marketing”

November 2005 (Vol. 4, Issue #10)

• Pharma Marketing Blog a “Must Read”
• DTC Pros and Cons Presented at FDA Hearing
• Predictive Physician Marketing
• GSK Strikes Back with a Grassroots Campaign
• Global Digital Asset Brand Management
• Sales Rep Assessment: Shoot the Messenger, the Message, or Both?

October 2005 (Vol. 4, Issue #9)

• Surveys Say…
• eDetailing: Yesterday, Today and Tomorrow
• Managing Cross Boundary Issues
• Society of Industry Leaders: Help for Investors
• Mobile Medical Reference: An Effective Door Opener for Sales Reps

September 2005 (Vol. 4, Issue #8)

• It’s the Science, Stupid!
• cDetailing: Addressing the Consumer Education Gap
• The Evolving Impact of Anti-Spam Legislation on Online Marketers
• Patient Detailing at the Point of Care
• Midwestern eMarketing Values

July/August 2005 (Vol. 4, Issue #7)

• Restrict DTC, but Extend the Patent for New Drugs
• To Ban or Not to Ban DTC, That is the Question
• Marketing the Pharma Industry: The Empire Strikes Back
• Translate Industry Trends into the Optimal Promotional Strategy
• A Call to Action: A Mea Non Culpa by Big Pharma

June 2005 (Vol. 4, Issue #6)

• Transparency is the Word These Days
• Compliance with (Some) New ACCME Rules Not So Easy
• Protecting Your Brand with Anti-Counterfeiting Solutions
• Limbic Market Research: Plumbing the Subconscious Motivators of Physicians
• Drug Risk Survey Results
• A Strategic Approach to CME Offers High Return on Education Investment
• Pharma BloggoSphere Update

May 2005 (Vol. 4, Issue #5)

• A Good Time Was Had by All
• A Proposal for a Drug Risk Advisory System
• Thought-Leader Management: A Challenge Met
• Marketing in the Post-Vioxx Era
• Return on CME: Are Pharma Companies Getting Desired Outcomes?
• Is Pharma Marketing a Lot of BS?

April 2005 (Vol. 4, Issue #4)

• Separation of Church and State
• E-mail Marketing Best Practices for Pharma
• Measuring Marketing Strategy
• Beyond the eDetail: Evolving to Educate
• Growing Pharmaceutical Sales Utilizing Six Sigma and Lean
• Survey Results: Straight-Talking DTC

March 2005 (Vol. 4, Issue #3)

• Give Docs What They Want
• Marketing’s Role in Limiting Physician Access and What to Do About It
• Increase Prescription Sales with Smart Tools
• How to Sell a Drug Before it is Approved
• Leverage Health Beliefs to Develop Effective Online Compliance Programs
• Applying FDA Marketing Regulations to Internet Promotions
• Cost-Cutting Strategies for the Pharma Industry

February 2005 (Vol. 4, Issue #2)

• Times They Are A-Changing?
• You May Walk Like a Duck and Quack Like a Duck, But You’re No Duck!
• Relationship Marketing Program Management for Pharmaceutical Marketers
• DTC in 2005: Can You Teach Old Dogs New Tricks?
• Numbers, Math and Communicating Risk
• Does the FDA Need to be Overhauled?

January 2005 (Vol. 4, Issue #1)

• Blogging My Way Into 2005!
• Can Health Web Sites Improve Compliance?
• Facilitating Physician Access and Education Through Online Conferencing
• MSL Role in Educational Development
• Motivating & Retaining The MSL: What Makes MSLs Tick
• Managing Medical Science Liaisons From Afar
• A Web-based Therapy Management Program
• Drug Prices, Declining Profits Top Issues for 2005

---

2004

November/December 2004 (Vol. 3, Issue #10)

• Corporate “Moral Values” Anyone?
• The Truth About the Drug Companies: What To Do About It
• Creating a Successful DTC Campaign on the Inside
• A Novel Approach to Communicating with Physicians
• Is Your Product Ready for Consumers?
• Will COX-2 Inhibitors Crash and Burn?

October 2004 (Vol. 3, Issue #9)

• Vioxx Withdrawal and the “Me-Too Drug Domino Effect”
• Physician Adoption and Use of Technology at the Point of Care
• The Role of Tablet PCs in Pharma Sales and Marketing
• Strategies for Enhanced Physician Targeting and Segmentation
• No More Free Lunch in California?
• Drug Reimportation Survey Results

September 2004 (Vol. 3, Issue #8)

• Drug Importation Crisis: Terror Politics to the Rescue!
• The Indian Pharmaceutical Market
• Congress Fiddles While Reimportation Issue Burns
• Becoming Woman Wise: Marketing Healthcare to Women
• Accelerating Your Multicultural Communications
• How Cheap are Canada’s Drugs Really?

July/August 2004 (Vol. 3, Issue #7)

• The Price of Drugs
• California’s Physician Prescribing Act: A History of Twists and Turns
• A Crisis in Professional Detailing
• The Targeted Model: The Future of Pharmaceutical Marketing?

June 2004 (Vol. 3, Issue #6)

• Pharma eMarketing: A Level Playing Field or a Killing Field?
• Ready or Not: Gearing Up for the Expansion of ePrescribing
• ePrescribing: What Role Should Pharma Play?
• eDetailing Strategies for a Higher Physician Response
• The New Branding Model: From Blockbusters to Targeted Therapies
• Are ED Ads Too Sexually Explicit?

May 2004 (Vol. 3, Issue #5)

• Pushing the Envelope is Bad for DTC
• Searching for Answers on Search Engine Marketing?
• European Compliance Not Only Possible, But Leading Edge
• The Revitalized Brand: Creating a New Brand Image from an Old Product
• Branding as a Management Tool in Pharma
• Direct-To-Consumer Advertising: Developing Evidence-Based Policy To Improve Retention And Comprehension

April 2004 (Vol. 3, Issue #4)

• The Future of Big Pharma
• Intelligent Online Sampling Strategies
• The Internet and CME
• When Is Commercial Support Appropriate for CME Activities?
• Emotions, Focus and Storytelling: How Cialis is Challenging Viagra
• Maximizing the DTC Message: Healthcare Businesswomen’s Association Members Evaluate DTC Marketing

March 2004 (Vol. 3, Issue #3)

• Want to Know What Really Sucks?
• Scenarios on the Future of Pharma Marketing: No Time Like the Present to Think the Unthinkable
• Medical Science Liaisons: Working between Two Worlds
• Effective Pharma Adherence Programs Start With The Patient
• To Build Patient Adherence, Pfizer Puts Technology Behind The Curtain
• Your Pharma Marketing Sucks
• The New Written Prescription: Leveraging Technology to Measure Change in Physician Behavior as it Occurs

February 2004 (Vol. 3, Issue #2)

• Is DTC Educational or Motivational?
• Key Issues Facing DTC Marketers in 2004
• Beyond Patient Education: Influencing Behavior Change
• FDA Draft Guidance for Print DTCA: Less than Feared
• Super Bowl DTC Debut: Was It Good for You?
• Beyond DTC: Consumer Relationship Satisfaction

January 2004 (Vol. 3, Issue #1)

• Controlling Your Brand’s Switch Destiny
• Finding the “Right Stuff” to Revitalize Sales Productivity
• Spam spam spam spam. Lovely spam! Wonderful spam!
• Strategies for Overcoming the Internal Challenges between Rx and OTC
• What You Need to Know About the New “CAN-SPAM” Law

---

2003

December 2003 (Vol. 2, Issue #11)

• The FTC-Lilly Consent Decree: What it Means for PHARMA Vendors and Partners
• Guidelines for Off-label Communications
• Integrating Compliance into Commercial Practices
• Managing Privacy Risks in Your Commercial Practices
• PhRMA Code Succeeding…So Far
• Pharma’s Confidence Crisis: A Call for a New Marketing Paradigm?

November 2003 (Vol. 2, Issue #10)

• Balancing Idealistic vs. Realistic CRM Processes
• Developing Win-Win Key Opinion Leader Relationships
• Putting the Customer Back in Customer Relationship Management
• Relationships
• Tailoring CRM Solutions to Your Business Strategy

October 2003 (Vol. 2, Issue #9)

• The Future of eDetailing
• The Impact of eDetailing: Will it Complement, Replace, or Become Integrated with the Sales Force?
• Optimizing eDetailing ROI
• Why Pharma Can’t Ignore eDetailers

September 2003 (Vol. 2, Issue #8)

• Branding Internally: Think Brand, Not Product
• Evolve Your Brand into a Relationship with Consumers and Physicians
• What the Next Generation Physician Wants from Pharma

July 2003 (Vol. 2, Issue #7)

• Out-of-the-Box Marketing: Will It Work for Pharma?
• Patient-Level Data: A New Level of Analysis
• Understanding Drivers of Patient Behavior to Maximize DTC Effectiveness

June 2003 (Vol. 2, Issue #6)

• It’s All About Education
• Online CME – A Glass Half-Full or Half-Empty?
• Provider/Pharmaceutical Partnerships – Are They Possible Without Conflict of Interest?
• Responding to the Challenges of Evolving Regulation
• Understanding the Proposed ACCME Standards for Commercial Support

May 2003 (Vol. 2, Issue #5)

• Drug Marketers Need More Than Demographic Data To Effectively Market To Consumers
• Ethical Online Practices Build Consumer Trust
• Pharmaceutical Marketing in Texas: look out for state privacy laws!
• Proactive e-Marketing Plan
• Product Branding, e-Marketing May Be Underutilized

April 2003 (Vol. 2, Issue #4)

• e-Marketing at the Point of Care
• Pharma Marketing Network Survey Results
• PhRMA Code Helps Re-define Roles of Medical Affairs and Marketing

March 2003 (Vol. 2, Issue #3)

• Consumer Use of the Internet for Health: Whose Numbers Do You Believe?
• Integrating Online & Offline Marketing: Challenges for Pharma

February 2003 (Vol. 2, Issue #2)

• Quality of Pharma-sponsored Health Information on the Internet

January 2003 (Vol. 2, Issue #1)

• Has DTC Spending Peaked?
• Online and Offline Professional and Consumer Marketing
• Results from FDA Physician Survey on DTC Advertising
• Top Companies, Classes, and Products in the DTC Space

---

2002

November 2002 (Vol. 1, Issue #9)

• Is Pharma Ready for HIPAA?
• Texas Medical Privacy Act: A Wolf in Sheep’s Clothing?

October 2002 (Vol. 1, Issue #8)

• Personalized e-Marketing – How can you create and profit from a customer’s lifetime experience?
• What Stands in the Way of the Mainstream Use of the Internet by Pharmaceutical Companies?

September 2002 (Vol. 1, Issue #7)

• The Absolute, Relative, and Incremental ROI of DTC e-Marketing
• Product Web Sites: Are They Worth It?

February 2002 (Vol. 1, Issue #2)

• Pharmaceutical Compliance with Fair Information Practice Principles

Choose a Reprint by Title Choose letter:
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | Y |

A…

• The Absolute, Relative, and Incremental ROI of DTC e-Marketing
• Accomplishing Adherence
• Accountability for Pharma Content on Social Media Sites
• A Call to Action: A Mea Non Culpa by Big Pharma
• A Few Things I Learned at FDA’s Social Media Hearing
• A Good Time Was Had by All
• Ad Dollars Follow Eyeballs to Web
• Americans Skeptical of Pharma Cause Marketing
• An Online Community to Call Our Own
• Applying FDA Marketing Regulations to Internet Promotions
• Are Pharma Bloggers Biased Against the Industry?
• Are Sales Reps Necessary?
• Awards. What Are They Good For?

B…

• Balancing Idealistic vs. Realistic CRM Processes
• Betting the Pharm
• Beyond DTC: Consumer Relationship Satisfaction
• Beyond Patient Education: Influencing Behavior Change
• Beyond the eDetail: Evolving to Educate
• Big Pharma Sales Analytics for the Rest of Us
• Biotech DTC: Business Not As Usual
• Blogging My Way Into 2005!
• Blogs and the Pharmaceutical Industry
• Branded Physician Education: How to Integrate Promotion and Education
• Branding Internally: Think Brand, Not Product
• The Brand Marketing Mix
• British Pharma Digital Update: Insider Reactions to Social Media Guidelines from Industry Regulators
• Brits Beat FDA & PhRMA: Issue Social Media Guidance for Pharma
• Building a Blockbuster
• Building the “New” Pharma Physician Marketing Model
• Building the Optimal Service Model: Creating the Right Physician Experiences to Drive Business
• Building Power Sales Messages
• Buzz ‘n Blog Marketing

C…

• California’s Physician Prescribing Act: A History of Twists and Turns
• Can Health Web Sites Improve Compliance?
• Capturing & Reporting HCP-Related Meeting Spending
• cDetailing: Addressing the Consumer Education Gap
• Challenges of Regulating Mobile Medical Apps
• The Changing Pharma Commercial Model in 2010 and Beyond
• The Changing Landscape of Physician Interactions
• The Changing Policy Landscape: Prepare Now for the Coming FDA and Pharmaceutical Marketing Reforms
• The Changing Role of Pharma Sales Reps
• The Changing World of MSLs: Determining Value
• Cholesterol Drug Users Discuss Their Medication
• Closed Loop Marketing
• Closed-Loop Patient Education
• Collaborating with Online Physician Communities
• The Coming Pharma Marketing Recession
• Communicating Risk: Let the Dialog Begin
• Compliance with (Some) New ACCME Rules Not So Easy
• Congress vs. Pharma: Trouble Ahead?
• Consequences of Direct-to-Consumer Advertising
• Consumer Use of the Internet for Health: Whose Numbers Do You Believe?
• Controlling Your Brand’s Switch Destiny
• Corporate Reputation in the New Media World
• Corporate “Moral Values” Anyone?
• Cost-Cutting Strategies for the Pharma Industry
• Could Chill Kill CME?
• Creating a Successful DTC Campaign on the Inside
• Creating the Most Effective Sales Calls
• A Crisis in Professional Detailing
• Critical: What Daschle Plans to Do About the Healthcare Crisis
• Current Issues and Future Prospects for Sales Force Effectiveness

D…

• Data Mining in the Deep, Dark Social Networks of Patients
• Developing Guidelines for Pharma’s Use of the Internet & Social Media: A Call for a Public Hearing at FDA
• Developing Win-Win Key Opinion Leader Relationships
• Digital Pharma Is Alive and Well in Europe!/A>
• Direct to Physician Telemarketing and Sales
• Disease Mongering
• Disease Mongering: When Is the Line Crossed?
• Diversity in the Life Sciences
• Diversity in Pharma
• DocCheck: Das Portal
• Does the FDA Need to be Overhauled?
• Doing a Good Job but Still Not Trusted!
• Drug Reimportation Survey Results
• Drug Marketers Need More Than Demographic Data To Effectively Market To Consumers
• Drug Prices, Declining Profits Top Issues for 2005
• Drug Risk Survey Results
• DTC, for Better or Worse, is Here to Stay
• DTC in 2005: Can You Teach Old Dogs New Tricks?
• DTC Pros and Cons Presented at FDA Hearing
• DTC Risk Communication
• DTC User Fees Go PDUffft!

E…

• eDetailing Technology & Birth of “Sales Cyborg”
• eDetailing: Yesterday, Today and Tomorrow
• The End of DTC as We Have Known It
• E-mail Marketing Best Practices for Pharma
• Emotions, Focus and Storytelling: How Cialis is Challenging Viagra
• e-Marketing at the Point of Care
• Effective Pharma Adherence Programs Start With The Patient
• Effective Physician Marketing at Medical Meeting Exhibits
• e-Inertia Plagues the Pharma Industry
• The Empowered Patient: What It Means for Pharma Marketers
• The ePharma Pioneer Club™: Convincing Pharma Marketers to Engage in “e”
• ePrints NRx for Physician Detailing
• The Electronic Formulary Will Change the Equation
• Engagement
• Ethical Online Practices Build Consumer Trust
• European Compliance Not Only Possible, But Leading Edge
• The European eMarketing Scene: Desperately Seeking Strategy
• European Online Marketing Survey Results
• Evolve Your Brand into a Relationship with Consumers and Physicians
• The Evolving Impact of Anti-Spam Legislation on Online Marketers
• Eyes on the Adherence Prize/A>
• The Expanding Pharma Blogosphere

F…

• Facilitating Physician Access and Education Through Online Conferencing
• Fast Start to Customized ePromotion and eLearning Physician Programs
• FDA Can Relax. I Did All the Work for Them!
• FDA, DOJ, & Google: Conspiracy Theory, Part 2
• FDA Drops “Social Media” from Its 2011 Guidance Agenda
• FDA Draft Guidance for Print DTCA: Less than Feared
• FDA Draft Guidance on Risk: Reading the Tea Leaves
• FDA Finalizes Guidance on Distribution of Reprints
• FDA’s Bad Ad Program is “Phoniest Thing Ever!”
• FDA’s BadAd Program Lacks Credible Evidence
• FDA’s Good Reprint Practices Guidance
• FDA’s Use of Social Media: Peanuts Today, Drugs Tomorrow!
• FDA Plans to Test New Standard for Easy to Understand Rx Labels
• FDA v. Google & Those 14 Infamous Warning Letters
• Fear and Loathing in Washington, DC
• Finding the Consumer Within the Patient
• Finding the “Right Stuff” to Revitalize Sales Productivity
• First FDA Social Media Guidance to Address Responding to “Unsolicited Requests” for Off-label Information
• Four Useful Lessons Pharma Can Learn from the Pfizer Facebook Hack
• Free Drug Samples: The Sales Rep’s Last Great Hope?
• Free Gifts to Physicians: What’s the Big Deal?
• Free Prescription Drug Cards
• From Nalty to “Nalts”: The Transformation of a Pharma Marketing Director into a “Viral Video Genius”
• From Science to CEO: The Scientific Path to Corporate Leadership
• The FTC-Lilly Consent Decree: What it Means for PHARMA Vendors and Partners
• The Future of Big Pharma
• The Future of DTC Advertising: Is a Perfect Storm Brewing?
• The Future of eDetailing

G…

• Generation Rx: A History and Critique of Pharma “Tribal Marketing”
• Getting Market Research Right in Emerging Markets
• Getting Market Research Right in the Middle East/A>
• Give Docs What They Want
• Global Digital Asset Brand Management
• Global Pharma Competitive Intelligence
• God Bless R&D, but Marketers May Go to Hell!
• Good Promotion Practices Alliance
• Got Game? Online Pharma Advergaming
• Growing Pharmaceutical Sales Utilizing Six Sigma and Lean
• GSK Strikes Back with a Grassroots Campaign
• Guerilla Pharma Marketing
• Guidelines for Off-label Communications

H…

• Hard Sell: The Evolution of a Generation X Salesman
• Has DTC Spending Peaked?
• Healthcare Communications vs. Pharma Marketing (pdf)
• Helping Pharma eMarketing “Grow up”
• High Impact Content in Support of Rx Brands
• How Readable, Credible & Useful are Pharma Blogs?
• How to Get Your Message In Front of Pharma Brand Managers
• How to Manage the Online Conversation
• How to Sell a Drug Before it is Approved
• How Should Pharma Engage in Social Networks?: Thoughts on Best Practices
• The Hypocrisy of Healthcare Marketing Restrictions: Stand Up for Healthcare Marketing Free Speech

I…

• I’m All a Twitter Over Twitter
• The Impact of eDetailing: Will it Complement, Replace, or Become Integrated with the Sales Force?
• Implications of Facebook’s Page Commenting Changes
• Increase Prescription Sales with Smart Tools
• India’s Booming Pharmaceutical Market
• Industry and Consumer Advocates Square Off Regarding Social Media
• Innerstate: The First Disease Awareness Documentary Film
• Integrating Compliance into Commercial Practices
• Integrating Online & Offline Marketing: Challenges for Pharma
• Integration of Custom Media into the Marketing Mix
• Intelligent Online Sampling Strategies
• The Internet and CME
• Interpretation of Ads
• The iPad as a Pharma Marketing Platform
• Is It Time to End Industry Sponsored CME?
• Is Pharma Ready for HIPAA?
• Is Pharma Marketing a Lot of BS?
• Is Your Product Ready for Consumers?
• It’s All About Education
• It’s the Science, Stupid!

J…

• J&J’s PR Hindenburg Disaster!
• Jarvik: A Modern DTC Tragedy
• Up Front: Just-in-Time Publishing

K…

• Key Issues Facing DTC Marketers in 2004

L…

• Let’s Respond to FDA’s Questions Regarding Its Regulation of Social Media
• Leverage Health Beliefs to Develop Effective Online Compliance Programs
• Limbic Market Research: Plumbing the Subconscious Motivators of Physicians
• (Little) Used Drug for Sale. GSK Says, Bye Bye Alli!

M…

• Managing Cross Boundary Issues
• Managing Medical Science Liaisons From Afar
• Managing Privacy Risks in Your Commercial Practices
• Managing Reprints for Better Clinical Support of Marketing
• Mapping New Paths through the DTC Marketing Mix Maze
• Marketing in the Post-Vioxx Era
• Marketing the Pharma Industry: The Empire Strikes Back
• Marketing’s Role in Limiting Physician Access and What to Do About It
• Maximizing the DTC Message: Healthcare Businesswomen’s Association Members Evaluate DTC Marketing
• Measuring an Intangible: Medical Science Liaison Metrics Consensus
• Measuring & Communicating eSuccess: Strategy First, YouTube Later… Maybe
• Measuring Marketing Strategy
• Measuring Consumer Sentiment About Prescription Drugs
• Medical Device Marketing
• Medical Science Liaisons: Working between Two Worlds
• Medical Transcript Advertising
• Merit of CHC Petition to FDA
• Merck Rejiggers Its Marketing Mix
• Midwestern eMarketing Values
• Mining Mobile Health App User Data
• Mobile Medical Reference: An Effective Door Opener for Sales Reps
• Mobile Pharma Marketing: What’s the 411?
• Moderation Best Practices for Pharma Social Networks
• Moore: Please Don’t Ignore Us Pharma Bloggers
• Motivating & Retaining The MSL: What Makes MSLs Tick
• Moving the Needle on Adherence
• MSL Role in Educational Development
• MSL Roles & Goals
• Murky Physician Marketing and Education Practices

N…

• A New Estimate of Drug Development Cost
• New Facebook Policy “Kind of Hurts” Pharma Marketers
• New Media Privacy Issues & Online Health Marketing
• The New PhRMA Code and Beyond: Federal & State Laws are Eclipsing Self-Regulation
• New Privacy Rules in Economic Stimulus Law: Will They Restrict Certain Pharmaceutical Marketing Practices?
• The New Rules of Marketing & PR: Book Review and Insights for Pharma
• New Social Media Regulatory Framework
• The New Written Prescription: Leveraging Technology to Measure Change in Physician Behavior as it Occurs
• No More Free Lunch in California?
• A Novel Approach to Communicating with Physicians
• Numbers
• Numbers, Math and Communicating Risk

O…

• Obama v. McCain Survey Results
• One…uh, Two Small Steps for Pharmaco Blogging!
• Online and Offline Professional and Consumer Marketing
• Online CME – A Glass Half-Full or Half-Empty?
• Optimizing Brand Equity: Pre-Launch through Patent Expiry and Beyond!
• Optimizing Market Access: A Guide to Effective Pricing, Reimbursement and Messaging Strategies
• Optimizing DTC Performance
• Optimizing eDetailing ROI
• Out-of-the-Box Marketing: Will It Work for Pharma?
• Overcoming Space Limitations in Social Media
• Owning the Prescription Pad: Driving Brand Decisions in a Multi-Influence World

P…

• Paid Inclusion: Too Hot for Pharma Marketing?
• Patient Assistance Program Rankings: Going Beyond Sales Force Effectiveness to Customer Experience Satisfaction
• Patient-Level Data: A New Level of Analysis
• Patient Detailing at the Point of Care
• Personalized e-Marketing – How can you create and profit from a customer’s lifetime experience?
• Peter Rost: Whistle Blower, Pharma Blogger, ???
• Pfizer France: Viva la SFE Difference!
• Pharma Begins to Reveal Payments to Physicians
• Pharma BloggoSphere Update
• Pharma Collaboration with Online Patient Opinion Leaders
• Pharma eMarketing: A Level Playing Field or a Killing Field?
• Pharma Even More Digitally Feeble When it Comes to Healthcare Providers
• Pharma Marketing Blog a “Must Read”
• Pharma Marketing Network 2007 Report
• Pharma Marketing Network Survey Results
• Pharma Marketing Stuck in Web 1.5
• Pharma’s Confidence Crisis: A Call for a New Marketing Paradigm?
• Pharma’s Plodding Approach to eMarketing
• Pharma’s Black Knight Confesses All!
• Pharma Marketing Roundtable – Members Only!
• Pharma McCarthyism
• Pharma Online Spending
• Pharma, Physicians, and Sermo
• Pharma SmartPhone/Tablet Apps: Is There a Regulation for That?
• Pharma’s Social Media Working Group
• Pharma Trends to Watch in 2006
• Pharmaceutical Competitive Intelligence
• Pharmaceutical Compliance with Fair Information Practice Principles
• Pharmaceutical Market Access 2010: Strategic Developments Impacting the US, EU, and Emerging Markets
• Pharmaceutical Marketing in Texas: look out for state privacy laws!
• The Pharmaguy Next Door
• Pharmaguy’s Twitter Followers: What Do They Want and How Is It Relevant to You?
• Pharmacy TeleStocking
• Pharma Marketers Dive Deeper Into Social Media: The Good, the Bad, & the Ugly Case Studies
• Up Front: Pharma’s 2010 Christmas Wish List for Santa
• Pharma’s Bad Rep or Bad Rap: Whatever! The Drug Industry Must Earn Back the Public’s Trust
• Pharma Facebook Pages Being Phased Out: A Good Run While It Lasted!
• Pharma’s Image Conundrum: Building Brand Loyalty and Consumer Confidence
• Pharma’s Social Media Marketing Readiness Score
• Pharma-Sponsored Medical Ghostwriting: What the Ghosts Have to Say About It
• Up Front: Pharma Crisis Communications in the Fast-paced World of Twitter et al
• Pharma TeleWeb e-Detailing
• Pharma Twitter Pioneers Recognized
• The Pharmaguy Social Media Timeline™
• Phil Mickelson is Now Regulated by FDA
• PhRMA Code Helps Re-define Roles of Medical Affairs and Marketing
• PhRMA Code Succeeding So Far
• PhRMA’s New Code on Interactions with Healthcare Professionals
• Physician Adoption and Use of Technology at the Point of Care
• Physicians Favor Brands With a Compelling Adherence Program
• Physician-Generated Content on Social Media Sites
• Physician Meetings: Education Works Both Ways
• Physicians Are Concerned That Pharma Supported CME is Biased, But …
• PR: Advertising by Other Means
• PR & Interactive Agencies Vie for Pharma Social Media Campaign Crumbs
• Predicting the Future of the Drug Industry
• Predictive Physician Marketing
• Up Front: Prepare or Die!
• Prescription Drugs and the Health 2.0 Opportunity
• The Price of Drugs
• A Primer on Pharma Employee Blogging
• Print DTC: How Does It Measure Up?
• Proactive e-Marketing Plan
• Product Branding, e-Marketing May Be Underutilized
• Product Web Sites: Are They Worth It?
• A Proposal for a Drug Risk Advisory System
• Protecting Your Brand with Anti-Counterfeiting Solutions
• Protection from Brand Infection: Marketers Must Take Control of Their Brands, Especially Online
• Provider/Pharmaceutical Partnerships – Are They Possible Without Conflict of Interest?
• Pushing the Envelope is Bad for DTC
• Putting the Customer Back in Customer Relationship Management

Q…

• Quality of Pharma-sponsored Health Information on the Internet

R…

• Ramifications of FDA Regulatory Actions: Helping FDA Find a New Media Regulatory Pathway
• Re-Designing the Pharma Sales Force
• Real Patient Testimonials
• Reforming the FDA: It All Starts with a New Commissioner!
• Reinventing the Sales Model
• Relationship Marketing via eNutrition
• Relationship Marketing Program Management for Pharmaceutical Marketers
• Relationships
• Rep Access Programs
• Report from the Social Pharmer “Unconference”: Sowing Seeds of Social Media Change?
• Reporting Gifts to Physicians
• Responding to the Challenges of Evolving Regulation
• Restrict DTC, but Extend the Patent for New Drugs
• Results from FDA Physician Survey on DTC Advertising
• Return on CME: Are Pharma Companies Getting Desired Outcomes?
• The Revitalized Brand: Creating a New Brand Image from an Old Product
• Risk Mitigation and Its Impact on Pharma Marketing: Appropriate Use Benefits After Launch
• The Role of Tablet PCs in Pharma Sales and Marketing

S…

• Sales Effectiveness Meets eMarketing
• Sales Force Effectiveness Metrics: More Important Than Ever in a Tough Market
• Sales Rep Assessment: Shoot the Messenger, the Message, or Both?
• Sales Reps Debate Their Value
• Scenarios on the Future of Pharma Marketing: No Time Like the Present to Think the Unthinkable
• Search Advertising Options for Pharma
• Searching for Answers on Search Engine Marketing?
• Separation of Church and State
• Should Bloggers Dine at Pharma’s Table?
• SiCKO is Boffo but Not Anti-Pharmaco Per Se
• Slides: The Currency of Communication
• Social Communications in Healthcare: Summary of Roundtable Discussions
• Social Media Adverse Event Reporting Safe Harbors: It’s Time for FDA to Open Up the Internet to Rx Advertising Like It Did with TV!
• Social Media and the Limitations of Disease Awareness Campaigns
• Social Media–Opportunity or Nightmare?
• Social Media & the Truncated News Pyramid
• Social Media Leaders Wanted
• Social Network Marketing: The Wisdom of the Crowd
• Socially Challenged Pharma: How Ready is Pharma to Engage In Social Media?>
• Society of Industry Leaders: Help for Investors
• Up Front: Solving the Adherence Problem in Economic Hard Times
• Solving the Social Media Adverse Event Reporting Problem
• Spam spam spam spam. Lovely spam! Wonderful spam!
• The State of CME in Europe
• Stop Wasting $Millions on Ineffective DTC Ads!
• Straight-Talking DTC Survey Results
• A Strategic Approach to CME Offers High Return on Education Investment
• Strategies for Enhanced Physician Targeting and Segmentation
• Strategies for Overcoming the Internal Challenges between Rx and OTC
• Super Bowl DTC Debut: Was It Good for You?
• Surfing the eMarketing Big One!
• Surveys Say…
• Surviving the Election Wars
• Up Front: Syndication is da Bomb!

T…

• Tailoring CRM Solutions to Your Business Strategy
• A Tale of Two Pharma Whistleblower Novels
• Targeted Faith-based Disease Awareness Marketing
• The Targeted Model: The Future of Pharmaceutical Marketing?
• Teaching New Dogs Old Tricks
• Texas Medical Privacy Act: A Wolf in Sheep’s Clothing?
• Thought-Leader Management: A Challenge Met
• Times They Are A-Changing?
• Tips for Improving Pharma Sales
• To Ban or Not to Ban DTC, That is the Question
• To Build Patient Adherence, Pfizer Puts Technology Behind The Curtain
• Top Companies, Classes, and Products in the DTC Space
• The Truth About the Drug Companies: What To Do About It
• Translate Industry Trends into the Optimal Promotional Strategy
• Transparency is the Word These Days
• Trends in Commercial Support of CME
• “Tribal Marketing”
• Turning Science into Sales

U…

• Understanding Drivers of Patient Behavior to Maximize DTC Effectiveness
• Understanding the Proposed ACCME Standards for Commercial Support
• Understanding the Strategic Value of MSLs
• Use of Behavioral Targeting by Pharma Marketers
• Use of Celebrities for PR and DTC Advertising
• Use of Social Media for Health Purposes in the EU
• Use of Twitter for Patient Support

V…

• Value-based Pricing
• Vast Majority of Drug Ads in Leading Medical Journals Don’t Pass MDs’ Sniff Test!
• The View From ePharma Summit: Practicing What Was Being Preached!
• Vioxx Withdrawal and the “Me-Too Drug Domino Effect”

W…

• Waiting for Goduidance (pdf)
• Waning Pharma Support of CME: The Plight of For-Profit MECCs
• Want to Know What Really Sucks?
• A Web-based Therapy Management Program
• Web 2.0 Pharma Marketing Tricks for Dummies
• What Americans Think About Drug Advertising
• What If There Were No Rules in Pharma Marketing?
• What Pharma Companies Spend on Gifts to Docs
• What Stands in the Way of the Mainstream Use of the Internet by Pharmaceutical Companies?
• What the Next Generation Physician Wants from Pharma
• What You Need to Know About the New “CAN-SPAM” Law
• What’s Next from the FDA?
• What’s Next vs. What’s Best
• Up Front: What’s Your Social Media Implementation Plan?
• When Is Commercial Support Appropriate for CME Activities?
• Who’s Better for Pharma: Obama or McCain?
• Whose Data Is It Anyway?
• Why Pharma Can’t Ignore eDetailers
• Why Pharmaceutical Marketers Ignore ROI
• Will COX-2 Inhibitors Crash and Burn?
• Will Healthcare be Rationed or Rational?: A Case for Supporting Comparative Effectiveness Research
• Will the Drug Industry be the Next Auto Industry?
• Whither CME?
• Whither Twitter for Pharma?
• Women in Pharma
• Word-of-Net

Y…

• You May Walk Like a Duck and Quack Like a Duck, But You’re No Duck!
• YouPharma: New Rules for Pharma Marketing and Social Media
• Your Pharma Marketing Sucks